Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01124630 · ClinicalTrials.gov registry record · Phase 1
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01124630 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 21 participants.
The verdict
NCT01124630, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Treatment with CS-1008 in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil \[5-FU\]) in subjects with metastatic colorectal cancer (CRC) who have failed first-line treatment that was not irinotecan-based.
Interventions
- DRUG FOLFIRI
- DRUG CS-1008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01124630
The ClinicalTrials.gov registry entry for NCT01124630 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FOLFIRI is the first listed.
NCT01124630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01124630 about?
NCT01124630 is a clinical study titled "Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments". Treatment with CS-1008 in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil \[5-FU\]) in subjects with metastatic colorectal cancer (CRC) who have failed first-line treatment that was not irinotecan-based.
What is the current status of trial NCT01124630?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2010-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01124630?
The interventions under investigation include: FOLFIRI (DRUG), CS-1008 (DRUG).
Who is sponsoring clinical trial NCT01124630?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.